Inogen's price performance has been poor this year, but a closer look at the numbers suggests that the market's negativity may be unwarranted. Management is actively taking steps to address the ...
Inogen Inc (NASDAQ:INGN), a medical technology company, reported fourth-quarter 2023 revenues of $75.90 million, missing the consensus of $76.99 million. Fourth quarter total revenue fell from $88.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback